4536 Stock Overview
Engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Santen Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,667.00 |
| 52 Week High | JP¥1,878.50 |
| 52 Week Low | JP¥1,291.00 |
| Beta | 0.21 |
| 11 Month Change | -7.52% |
| 3 Month Change | -8.10% |
| 1 Year Change | 25.10% |
| 33 Year Change | 6.25% |
| 5 Year Change | -19.51% |
| Change since IPO | 438.90% |
Recent News & Updates
Santen Pharmaceutical (TSE:4536) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Nov 18
Santen Pharmaceutical Co., Ltd. Just Beat EPS By 5.5%: Here's What Analysts Think Will Happen Next
Nov 11Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Share Price Could Signal Some Risk
Oct 14Recent updates
Santen Pharmaceutical (TSE:4536) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Nov 18Santen Pharmaceutical Co., Ltd. Just Beat EPS By 5.5%: Here's What Analysts Think Will Happen Next
Nov 11Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Share Price Could Signal Some Risk
Oct 14Calculating The Intrinsic Value Of Santen Pharmaceutical Co., Ltd. (TSE:4536)
Aug 31Santen Pharmaceutical Co., Ltd. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 08Unpleasant Surprises Could Be In Store For Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Shares
Jun 25Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
May 11Is There An Opportunity With Santen Pharmaceutical Co., Ltd.'s (TSE:4536) 34% Undervaluation?
May 08Shareholder Returns
| 4536 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -2.0% | -2.2% | -1.1% |
| 1Y | 25.1% | 14.7% | 11.5% |
Return vs Industry: 4536 exceeded the JP Pharmaceuticals industry which returned 14.7% over the past year.
Return vs Market: 4536 exceeded the JP Market which returned 11.5% over the past year.
Price Volatility
| 4536 volatility | |
|---|---|
| 4536 Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 3.9% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in JP Market | 7.6% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4536 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4536's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1890 | 3,744 | Takeshi Ito | www.santen.com |
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension.
Santen Pharmaceutical Co., Ltd. Fundamentals Summary
| 4536 fundamental statistics | |
|---|---|
| Market cap | JP¥577.36b |
| Earnings (TTM) | JP¥26.13b |
| Revenue (TTM) | JP¥302.56b |
22.1x
P/E Ratio1.9x
P/S RatioIs 4536 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4536 income statement (TTM) | |
|---|---|
| Revenue | JP¥302.56b |
| Cost of Revenue | JP¥127.31b |
| Gross Profit | JP¥175.26b |
| Other Expenses | JP¥149.13b |
| Earnings | JP¥26.13b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 75.44 |
| Gross Margin | 57.92% |
| Net Profit Margin | 8.64% |
| Debt/Equity Ratio | 0% |
How did 4536 perform over the long term?
See historical performance and comparisonDividends
2.0%
Current Dividend Yield45%
Payout RatioDoes 4536 pay a reliable dividends?
See 4536 dividend history and benchmarks| Santen Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Sep 27 2024 |
| Dividend Pay Date | Nov 29 2024 |
| Days until Ex dividend | 53 days |
| Days until Dividend pay date | 10 days |
Does 4536 pay a reliable dividends?
See 4536 dividend history and benchmarks